Rochester Medical Corporation

Rochester Medical — Shareholder Meeting (January 2010)

39 slides from Rochester Medical's shareholder meeting presentation, Jan 29, 2010

  1. Slide 1: Rochester Medical Corporation 2010 Annual Meeting

    Slide 1: Rochester Medical Corporation 2010 Annual Meeting

    Rochester Medical Corporation 2010 Annual Meeting January 28, 2010

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic r

  3. Slide 3: Outline

    Slide 3: Outline

    Outline Corporate Overview Revenue Growth Products Opportunities

  4. Slide 4: Company Facts

    Slide 4: Company Facts

    Company Facts Develop, Manufacture and Sell Disposable Incontinence and Bladder Drainage Devices Four Major Product Categories Rochester Medical Brand Sold in Over 75 Countries Focus on North America and Europe Private Label Sales to Major Medical Device Companies 28 Acres in Stewartville, Minnesota

  5. Slide 5: Sales - Brand Focused Growth, Private Label Stability

    Slide 5: Sales - Brand Focused Growth, Private Label Stability

    Sales -Brand Focused Growth Private Label "Stability" F04 F05 F06 F07 F08 F09* RM Branded 6551000 7351000 10797000 19226000 23848000 26331495 Private Label 2427665 8591000 10834000 13437000 11344000 11543445 *F09 if £ to $ exchange rates had not fallen (1.966 - 1.558)

  6. Slide 6: Q1 2010 Sales

    Slide 6: Q1 2010 Sales

    Q1 2010 Sales Q1-09 Q1-10 RM Branded 5564407 6722812 Private Label 2871677 3501977 21% Overall Sales Growth 25% U.S./U.K. Branded Growth 73% US Foley Sales Growth 30% US Intermittent Growth

  7. Slide 7: Market Opportunity

    Slide 7: Market Opportunity

    Market Opportunity Products/Markets U.S. U.K. Rest of Europe Total Male External Catheter $50 $18 $60 $128 Intermittent $400 $100 $300 $800 Foley/Urological Catheter $400 $50 $70 $520 TOTALS $850 $168 $430 1,448 ($ in millions) At Home Care At Home Care AcuteCare

  8. Slide 8: Marketing Overview

    Slide 8: Marketing Overview

    Marketing Overview Acute Care Homecare FemSoft

  9. Slide 9: Acute Care Recent Highlights

    Slide 9: Acute Care Recent Highlights

    Acute Care Recent Highlights: Introduced StrataSI Silicone Foley Catheters with Comfort Layered Technology The most significant advancement in 40 years Introduced StrataNF Anti-infection Foley Catheter The only anti-infection Foley Catheter indicated for reducing CAUTI Numerous hospitals at various

  10. Slide 10: Acute Care Recent Highlights: GPO Contracts

    Slide 10: Acute Care Recent Highlights: GPO Contracts

    Acute Care Recent Highlights: Two new GPO contracts Broadlane Premier (3yr renewal) 90% of US Market is Latex We believe Strata Technology obsoletes the need for Latex Strata Technology gives hospitals all the benefits of silicone without sacrificing comfort StrataNF is the only Foley Catheter indic

  11. Slide 11: Acute Care Communications Campaign: Direct Mail

    Slide 11: Acute Care Communications Campaign: Direct Mail

    Acute Care Communications Campaign Direct Mail

  12. Slide 12: Acute Care Communications Campaign: Trade Shows

    Slide 12: Acute Care Communications Campaign: Trade Shows

    Acute Care Communications Campaign Aggressive trade show promotion SHEA/ IDSA/ APIC Decennial AUA APIC

  13. Slide 13: Acute Care Communications Campaign: Journal Advertising

    Slide 13: Acute Care Communications Campaign: Journal Advertising

    Acute Care Communications Campaign Targeted high visibility journal advertising

  14. Slide 14: Homecare 2009 Highlights

    Slide 14: Homecare 2009 Highlights

    Homecare 2009 Highlights: Launched Magic3 Intermittent Catheters

  15. Slide 15: Homecare: Magic is Best in Class

    Slide 15: Homecare: Magic is Best in Class

    Homecare Magic is Best in Class Unique composite Three distinct Layers Easy Handling Gentle on sensitive tissue Proprietary Hydrophilic Surface Proprietary Antibacterial Surface

  16. Slide 16: Homecare DTC Campaign: Targeted Journal Advertising

    Slide 16: Homecare DTC Campaign: Targeted Journal Advertising

    Homecare DTC Campaign: Targeted Journal Advertising

  17. Slide 17: Homecare DTC Campaign: End User Events

    Slide 17: Homecare DTC Campaign: End User Events

    Homecare DTC Campaign: End User Events

  18. Slide 18: Homecare DTC Campaign: Direct Mail

    Slide 18: Homecare DTC Campaign: Direct Mail

    Homecare DTC Campaign: Direct Mail

  19. Slide 19: Homecare Communications Campaign: DTC Micro-site

    Slide 19: Homecare Communications Campaign: DTC Micro-site

    Homecare Communications Campaign: DTC - Micro-site

  20. Slide 20: Homecare Communications Campaign: DTC Brochure

    Slide 20: Homecare Communications Campaign: DTC Brochure

    Homecare Communications Campaign: DTC - Brochure

  21. Slide 21: FemSoft 2009 Highlights

    Slide 21: FemSoft 2009 Highlights

    FemSoft 2009 Highlights: Completed CMS application for reimbursement Granted unique HCPCS code Medicare coverage initiated Jan.1, 2010 Approved for reimbursement in the UK UK coverage initiated Jan. 1, 2010

  22. Slide 22: FemSoft 2010 Pilot Market Introductions

    Slide 22: FemSoft 2010 Pilot Market Introductions

    FemSoft 2010 Pilot Market Introductions: Charlotte, NC specialty clinic focus Southern Florida field rep / direct-market distributor focus

  23. Slide 23: FemSoft Communications Campaign

    Slide 23: FemSoft Communications Campaign

    FemSoft Communications Campaign: Print Advertising Out-of-Home Advertising Television Ad Lead/Referral/Follow-up Process

  24. Slide 24: FemSoft Communications Campaign: Print Advertising

    Slide 24: FemSoft Communications Campaign: Print Advertising

    FemSoft Communications Campaign: Print Advertising: Regional placements in magazines with readership by women in target audience Cosmo, Elle, Fitness, Health, Country Living, House Beautiful, Cooking Light, Food & Wine, to name a few!

  25. Slide 25: FemSoft: Live with confidence...

    Slide 25: FemSoft: Live with confidence...

    FemSoft Live with confidence...

  26. Slide 26: FemSoft Communications Campaign: Out of Home

    Slide 26: FemSoft Communications Campaign: Out of Home

    FemSoft Communications Campaign: Out of home: Restroom advertising in salons, shopping centers, restaurants, fitness centers Tear-off pad with clear call-to-action

  27. Slide 27: FemSoft Communications Campaign: Television

    Slide 27: FemSoft Communications Campaign: Television

    FemSoft Communications Campaign: Television: 30-second spot that brings silhouettes to life Modern, elegant, up-beat and positive messaging Clear, memorable call-to-action

  28. Slide 28: FemSoft Communications Campaign: DTC Micro-site

    Slide 28: FemSoft Communications Campaign: DTC Micro-site

    FemSoft Communications Campaign: DTC - micro-site:

  29. Slide 29: FemSoft Commercial

    Slide 29: FemSoft Commercial

    "| FemSoft Commercial

  30. Slide 30: Recent Customer Feedback

    Slide 30: Recent Customer Feedback

    Recent Customer Feedback "FemSoft saved my life! (Before FemSoft) I had to quit working. When I found out about them, it really improved my life." "I can ride bike without worry. It takes little practice but worth while." "I have been able to go walk and shop without fear of getting wet."

  31. Slide 31: Recent Customer Feedback

    Slide 31: Recent Customer Feedback

    Recent Customer Feedback "Start using them as soon as possible - they will give you your freedom back." "FemSoft is easy, comfortable and reliable! Don't be miserable, be safe with FemSoft! Would not be able to play tennis without FemSoft." "It is easy to use, comfortable to the point that I forget

  32. Slide 32: New FemSoft Opportunity

    Slide 32: New FemSoft Opportunity

    CMS Approval for Individual Code for FemSoft in the U.S. Drug Tariff approval in the U.K. New Femsoft Opportunity

  33. Slide 33: FemSoft: Only device of its kind

    Slide 33: FemSoft: Only device of its kind

    Only device of its kind Advanced, proprietary, patented Elegant solution for female incontinence Unique to Rochester Medical

  34. Slide 34: U.S. FemSoft Potential

    Slide 34: U.S. FemSoft Potential

    U.S. FemSoft Potential 12,000,000 Clinically Incontinent Females 5% Penetration = 600,000 Users At Current Reimbursement Assuming 2 devices per day = $937,320,000

  35. Slide 35: U.K. FemSoft Potential

    Slide 35: U.K. FemSoft Potential

    U.K. FemSoft Potential 2,400,000 Clinically Incontinent Females 5% Penetration = 120,000 Users At Newly Approved Reimbursement Assuming 2 devices per day = $210,240,000

  36. Slide 36: FemSoft Market Acceptance Difficult to Predict

    Slide 36: FemSoft Market Acceptance Difficult to Predict

    FemSoft Market Acceptance Difficult to Predict Stress Incontinence is a very significant problem Current Users satisfied with FemSoft solution However, most women's first reaction to concept of urethral insertion is hesitancy, caution, uncertainty. Consumer and clinical education needed to instill c

  37. Slide 37: Summary: Excellent Opportunities

    Slide 37: Summary: Excellent Opportunities

    Summary Excellent Opportunities Rochester Medical in strong position to achieve success Superior, advanced products and technology New market dynamics (reimbursement policies) New focus on infection control Core structure in place Magic Intermittents off to a great start! StrataSI and StrataNF off t

  38. Slide 38: FemSoft Commercial

    Slide 38: FemSoft Commercial

    "| FemSoft Commercial

  39. Slide 39: Forward Looking Statements

    Slide 39: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic r

Source: SEC EDGAR · 8-K filed Jan 29, 2010

More decks from Rochester Medical Corporation